Johnson & Johnson (NYSE: JNJ) is a Healthcare company in the Drug Manufacturers - General industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
267.08
-2.04-0.76%
News
Down 0.8% — What Eli Lilly Was Telling You While It Rationed Its Own Launches (Yahoo).
Medium confidence
TA
Loading chart...
Snapshot
| Index | S&P 500, DJIA | P/E | 30.95 | EPS (ttm) | 8.63 | Insider Own | 0.06% | Shs Outstand | 2.41B | Perf Week | -1.52% |
| Market Cap | 643.64B | Forward P/E | 20.91 | EPS next Y | 12.77 | Insider Trans | -18.26% | Shs Float | 2.41B | Perf Month | 2.01% |
| Enterprise Value | 671.91B | PEG | 2.64 | EPS next Q | 2.90 | Inst Own | 68.20% | Short Float | 0.90% | Perf Quarter | 12.69% |
| Income | 21.04B | P/S | 6.57 | EPS this Y | 34.23% | Inst Trans | 0.00% | Short Ratio | 2.65 | Perf Half Y | 9.59% |
| Sales | 97.93B | P/B | 7.57 | EPS next Y | 10.28% | ROA | 10.46% | Short Interest | 21.59M | Perf YTD | 29.06% |
| Book/sh | 35.26 | P/C | 31.01 | EPS next 5Y | 11.72% | ROE | 25.74% | 52W High | 281.08 -4.98% | Perf Year | 49.94% |
| Cash/sh | 8.61 | P/FCF | 35.45 | EPS past 3/5Y | 17.90% 14.89% | ROIC | 13.89% | 52W Low | 173.33 54.09% | Perf 3Y | 66.43% |
| Dividend Est. | 5.36 (2.01%) | EV/EBITDA | 19.92 | Sales past 3/5Y | 5.60% 2.67% | Gross Margin | 70.45% | Volatility | 1.81% 1.78% | Perf 5Y | 54.27% |
| Dividend TTM | 5.28 (1.98%) | EV/Sales | 6.86 | EPS Y/Y TTM | 49.05% | Oper. Margin | 26.81% | ATR (14) | 5.56 | Perf 10Y | 122.72% |
| Dividend Ex-Date | Aug 25, 2026 | Quick Ratio | 0.81 | Sales Y/Y TTM | 10.25% | Profit Margin | 21.48% | RSI (14) | 50.33 | Recom | 2.55 |
| Dividend Gr. 3/5Y | 4.92% 5.25% | Current Ratio | 1.09 | EPS Q/Q | 4.69% | SMA20 | -0.71% | Beta | 0.20 | Target Price | 284.79 |
| Payout | 59.99% | Debt/Eq | 0.59 | Sales Q/Q | 6.60% | SMA50 | 1.85% | Rel Volume | 0.76 | Prev Close | 269.12 |
| Employees | 141,700 | LT Debt/Eq | 0.48 | Earnings | Oct 13 | SMA200 | 12.93% | Avg Volume | 7.76M | Price | 267.08 |
| IPO Date | Jan 02, 1962 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 1.59% 0.99% | Net Debt/EBITDA | 0.85 | Volume | 5,862,062 | Change | -0.76% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-02-26 | Reiterated | UBS | Buy | $214 → $320 |
| Aug-06-26 | Reiterated | Guggenheim | Buy | $270 → $287 |
| Aug-03-26 | Reiterated | Raymond James | Outperform | $265 → $280 |
| Aug-03-26 | Reiterated | Wells Fargo | Overweight | $272 → $282 |
| Jul-29-26 | Reiterated | Argus Research | Buy | $290 → $300 |
| Jul-16-26 | Reiterated | Johnson Rice | $261 → $280 | |
| Jul-16-26 | Reiterated | Scotiabank | Sector Outperform | $265 → $305 |
| Jul-16-26 | Reiterated | Goldman Sachs | Buy | $275 → $282 |
| Jul-16-26 | Reiterated | Morgan Stanley | Overweight | $284 → $294 |
| Jul-16-26 | Reiterated | Raymond James | Outperform | $209 → $265 |
Latest News· Times ET
Sep-09-26
09:57AM
09:03AM
06:10AM
06:08AM
04:19AM
Compass Pathways stock rises as 52-week data show lasting depression reliefproactiveinvestors.com
Sep-08-26
Sep-08-2602:51PM
10:59AM
10:30AM
10:00AM
07:10AM
Cramer Says It's Time To Buy The Dip on JNJ247wallst.com
04:40AM
04:00AM
03:50AM
01:02AM
Company
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Ownership
Total institutional ownership68.20%
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/28/2025 | FY 2024 12/29/2024 | FY 2023 12/31/2023 | FY 2022 1/1/2023 | FY 2021 1/2/2022 | FY 2020 1/3/2021 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 97,929 | 94,193 | 88,821 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 28,936 | 25,635 | 27,471 | — | — | — | — | — | — | |
| Gross Profit | 68,993 | 68,558 | 61,350 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 25,141 | 23,676 | 21,969 | — | — | — | — | — | — | |
| Research and Development | 15,104 | 14,665 | 17,232 | — | — | — | — | — | — | |
| Other Operating Expense | 2,492 | 4,621 | 0 | — | — | — | — | — | — | |
| Operating Income | 26,256 | 25,596 | 22,149 | — | — | — | — | — | — | |
| Interest Expense | 1,012 | 971 | 755 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -48 | 7,956 | -4,707 | — | — | — | — | — | — | |
| Net Income Before Taxes | 25,196 | 32,581 | 16,687 | — | — | — | — | — | — | |
| Income Taxes | 4,159 | 5,777 | 2,621 | — | — | — | — | — | — | |
| Consolidated Net Income | 21,037 | 26,804 | 14,066 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 21,037 | 26,804 | 14,066 | — | — | — | — | — | — | |
| Net Income | 21,037 | 26,804 | 14,066 | — | — | — | — | — | — | |
| EPS (Recurring) | 8.65 | 11.03 | 5.84 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 8.65 | 11.03 | 5.84 | — | — | — | — | — | — | |
| EPS (Diluted) | 8.63 | 11.03 | 5.79 | — | — | — | — | — | — | |
| EBITDA | 33,732 | 41,055 | 24,781 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 30.95 | 18.82 | 25.05 | — | — | — | — | — | — | |
| Price To Sales Ratio | 6.65 | 5.35 | 3.93 | — | — | — | — | — | — | |
| Gross Margin | 70.45 | 72.78 | 69.07 | — | — | — | — | — | — | |
| Operating Margin | 26.81 | 27.17 | 24.94 | — | — | — | — | — | — | |
| Net Margin | 21.48 | 28.46 | 15.84 | — | — | — | — | — | — | |
| Shares Outstanding | 2,440 | 2,429 | 2,407 | — | — | — | — | — | — | |
| Market Capitalization | 651,675 | 504,333 | 349,135 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Schmid Timothy | EVP, WW Chair, MedTech | Sep 02 '26 | Sale | 274.74 | 22,527 | 6,189,068 | 25,447 | Sep 04 |
| Schmid Timothy | EVP, WW Chair, MedTech | Sep 02 '26 | Option Exercise | 144.99 | 33,597 | 4,871,389 | 47,974 | Sep 04 |
| Taubert Jennifer L | EVP, WWC. Innovative Medicine | Aug 17 '26 | Option Exercise | 115.67 | 15,000 | 1,735,050 | 209,451 | Aug 18 |
| Taubert Jennifer L | EVP, WWC. Innovative Medicine | Aug 17 '26 | Sale | 263.36 | 15,000 | 3,950,400 | 194,451 | Aug 18 |
| Duato Joaquin | CEO and Chairman of the Board | Aug 13 '26 | Sale | 261.17 | 123,291 | 32,199,927 | 275,967 | Aug 14 |
| Duato Joaquin | CEO and Chairman of the Board | Aug 13 '26 | Option Exercise | 115.67 | 123,291 | 14,261,070 | 399,258 | Aug 14 |
| Forminard Elizabeth | EVP, Chief Legal Officer | Aug 06 '26 | Option Exercise | 131.94 | 9,344 | 1,232,847 | 32,912 | Aug 07 |
| Forminard Elizabeth | EVP, Chief Legal Officer | Aug 06 '26 | Sale | 257.00 | 15,918 | 4,090,960 | 16,994 | Aug 07 |
| Duato Joaquin | CEO and Chairman of the Board | Aug 05 '26 | Sale | 258.15 | 48,480 | 12,515,010 | 275,967 | Aug 07 |
| Broadhurst Vanessa | EVP, Global Corp Affairs | Jul 20 '26 | Option Exercise | 130.77 | 23,054 | 3,014,702 | 46,057 | Jul 21 |
| Broadhurst Vanessa | EVP, Global Corp Affairs | Jul 20 '26 | Sale | 251.27 | 23,054 | 5,792,686 | 23,003 | Jul 21 |
| Wengel Kathryn E | EVP, Chief TO and Risk Officer | Jun 11 '26 | Option Exercise | 115.67 | 10,000 | 1,156,700 | 124,288 | Jun 12 |
| Wengel Kathryn E | EVP, Chief TO and Risk Officer | Jun 11 '26 | Sale | 241.15 | 10,000 | 2,411,500 | 114,288 | Jun 12 |
| REED JOHN C | EVP, Innovative Medicine, R&D | May 01 '26 | Option Exercise | 0.00 | 25,255 | 0 | 35,913 | May 04 |
| Decker Robert J | VP Corporate Controller | Feb 27 '26 | Option Exercise | 115.67 | 4,075 | 471,355 | 27,757 | Mar 03 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.